Company: CSTL
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0001447362-25-000054
Chunk: 95

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 95
---
 “Director Compensation.”

#### 86Castle Biosciences 2025 Proxy Statement
| Transactions with Related Persons and Indemnification |

Employment of Immediate Family Members of Executive Officers

Three of Derek J. Maetzold’s children, John Maetzold, Emily Kirk and Peter Maetzold and his brother-in-law, Greg Holzapfel are employed by the Company in non-officer positions. John Maetzold is a National Sales Director, Emily Kirk is an Executive Area Manager, Peter Maetzold is a Program Manager and Greg Holzapfel is our Director of Cyber Security & Infrastructure. For the year ended December 31, 2024, John Maetzold, Emily Kirk, Peter Maetzold and Greg Holzapfel received aggregate compensation of $897,469, $346,423, $336,851, and $493,498, respectively, of which $189,032, $46,918, $39,360, and$60,718, respectively, represents the aggregate grant date fair value of stock awards granted in 2024.

Tobin W. Juvenal’s son, Ryan Juvenal is employed by the Company in a non-officer position. Ryan Juvenal is a Senior Regional Business Director. For the year ended December 31, 2024, Ryan Juvenal received aggregate compensation of $446,323. For 2024, $60,718 represents the aggregate grant date fair value of stock awards.

Kristen M. Oelschlager’s two children, Allysa Topel, Shelby Oelschlager, and son-in-law, Joshua Albers are or were employed by the Company in non-officer positions. Allysa Topel was an Associate Director of Strategy and Clinical Services, employed by the Company until December 2024. Shelby Oelschlager is a Clinical Research Associate II and Joshua Albers is our Director of Software & Application Development. For the year ended December 31, 2024, Allysa Topel, Shelby Oelschlager and Joshua Albers received aggregate compensation of $241,848, $181,978 and $479,737, respectively, of which $39,360, $24,751, and $60,718, respectively, represents the aggregate grant date fair value of stock awards granted in 2024.

The 2023 annual stock award was shifted from the fourth quarter of 2023 to the first quarter of the proceeding year, after reporting of 2023 year-end earnings